Magic mushroom compound shows promise for depression in major trial
NCT ID NCT03866174
First seen Apr 25, 2026 · Last updated May 05, 2026 · Updated 2 times
Summary
This study tested whether a single 25 mg dose of psilocybin (the active ingredient in magic mushrooms) can reduce depression symptoms in adults with major depressive disorder. 347 participants received either psilocybin or an active placebo (niacin) and were followed for 43 days. The main goal was to see if psilocybin leads to greater improvement in depression scores compared to placebo.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DEPRESSIVE DISORDER, MAJOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Cedar Clinical Research
Draper, Utah, 84020, United States
-
Emory University
Atlanta, Georgia, 30322, United States
-
Great Lakes Clinical Trials
Chicago, Illinois, 60640, United States
-
Hassman Research Institute
Berlin, New Jersey, 08009, United States
-
Johns Hopkins University
Baltimore, Maryland, 21229, United States
-
New York University School of Medicine
New York, New York, 10016, United States
-
Pacific Neuroscience Institute
Santa Monica, California, 91404, United States
-
Segal Trials
Lauderhill, Florida, 33319, United States
-
University of California, San Francisco
San Francisco, California, 94121, United States
-
University of Wisconsin - Madison
Madison, Wisconsin, 53706, United States
-
Yale University
New Haven, Connecticut, 06520, United States
Conditions
Explore the condition pages connected to this study.